Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2

The Lancet Neurology in conversation with - A podcast by The Lancet Group - Thursdays

Categories:

Education

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology. Read the full article: Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL) Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/...